Cost-Effectiveness of Ventricular Assist Device Therapy as
a Bridge to Transplantation Compared With Nonbridged
Cardiac RecipientsClinical Perspective
by Ana C. Alba, Luis F. Alba, Diego H. Delgado, Vivek Rao, Heather J. Ross, and
Ron Goeree
Circulation
Volume 127(24):2424-2435
June 18, 2013
Copyright © American Heart Association, Inc. All rights reserved.
Markov model for heart transplantation (HTx) and ventricular assist device (VAD) as a bridge to
transplantation as treatment strategies for heart transplantation candidates.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Estimated model survival (A) and cumulative costs (B) according to baseline hemodynamic
status (high, medium, and low risk) and treatment strategy: ventricular assist device (VAD) as a
bridge to transplantation (VAD groups) or nonbridged heart transplant (HTx) recipients (HTx
groups).
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Cost-effectiveness plane.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being
cost-effective relative to heart transplantation (HTx) according to willingness to pay based on
baseline hemodynamic profile (high, medium, and low risk).
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being
cost-effective relative to heart transplantation (HTx) according to willingness to pay based on
the development of posttransplantation and post-VAD complications in high- (A), medium- (B),
and low-risk (C) patients with heart failure.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being
cost-effective relative to heart transplantation (HTx) according to willingness to pay based on
patients’ blood group type in high- (A), medium- (B), and low-risk (C) patients with heart failure.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being
cost-effective relative to heart transplantation (HTx) according to willingness to pay based on
patients’ age in high- (A), medium- (B), and low-risk (C) patients with heart failure.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.
Probability of therapy with ventricular assist device as bridge to transplantation (VAD) being
cost-effective relative to heart transplantation (HTx) according to willingness to pay based on
presence of renal dysfunction (defined as creatinine >1.5 mg/dL) in high-, medium-, and low-risk
patients.
Ana C. Alba et al. Circulation. 2013;127:2424-2435
Copyright © American Heart Association, Inc. All rights reserved.